{"recordId":"st_kxkhega45d94dwk0","canonicalUrl":"https://sotwire.com/stories/fortrea-completes-45-million-worldwide-early-phase-acquisition","jsonUrl":"https://sotwire.com/stories/fortrea-completes-45-million-worldwide-early-phase-acquisition/record","slug":"fortrea-completes-45-million-worldwide-early-phase-acquisition","headline":"Fortrea closes $45 million deal for Worldwide's early phase unit","dek":"The Durham CRO adds a 200-bed clinical research unit and a bioanalytical lab in Texas, bought from RTP-based Worldwide Clinical Trials.","articleBody":"Fortrea, the Durham contract research organization, said on Oct. 19, 2026, that it has completed its purchase of the Early Phase Services division of Worldwide Clinical Trials, a CRO based in Research Triangle Park. Fortrea valued the all-cash deal at about $45 million.\n\nThe division includes a 200-bed clinical research unit in San Antonio, a 60,000-square-foot bioanalytical laboratory in Austin and a biospecimen storage facility in Pflugerville, Texas. Fortrea says the purchase brings its early clinical development capacity to more than 570 beds worldwide and gives it in-house large and small molecule bioanalytical work. The acquired operations now sit inside Fortrea's Clinical Pharmacology Services business unit.\n\nFortrea says the combined platform is designed to reduce handoffs between clinical and bioanalytical teams and improve turnaround times for early-phase studies. \"Completing this acquisition further strengthens our integrated, scalable and scientifically differentiated clinical development platform,\" CEO Anshul Thakral said in the release.\n\nWorldwide said the sale lets it focus investment on its clinical development business in oncology, neuroscience, internal medicine and rare disease, and that it will keep offering healthy volunteer studies through its external site network. The two companies have signed agreements meant to keep client programs running through the transition.\n\nBarclays was Fortrea's financial advisor and Mintz its legal counsel. BroadOak Partners advised Worldwide, with Greenberg Traurig as legal counsel.","category":"other","categoryLabel":"Company news","location":"Durham, NC","company":{"name":"Fortrea","domain":"fortrea.com"},"sample":false,"sampleDisclaimer":null,"publishedAt":"2026-10-26T13:56:14.647Z","updatedAt":"2026-10-26T13:56:14.647Z","badge":"Desk reported","trust":{"level":"desk_reported","doctrine":"Sotwire verifies who at the company stood behind the submission. It does not independently certify every underlying company claim as true.","verifies":"which named Sotwire editor wrote this from the cited sources","doesNotCertify":"independent truth of every claim","badge":"Desk reported","verificationMethod":"Named Sotwire editor, from the cited sources. Not a company attestation, and not an independent fact-check of every sentence.","domainChecked":false},"attestation":{"attested":false},"confirmation":null,"facts":[{"label":"Deal value","value":"About $45 million, all cash"},{"label":"Closed","value":"Oct. 19, 2026"},{"label":"Seller","value":"Worldwide Clinical Trials (Research Triangle Park)"},{"label":"Sites added","value":"San Antonio clinical research unit (200 beds), Austin bioanalytical lab (60,000 sq. ft.), Pflugerville biospecimen storage"},{"label":"Early-phase capacity","value":"More than 570 beds globally, per Fortrea"},{"label":"Fortrea CEO","value":"Anshul Thakral"}],"keyEvents":[{"date":"2026-10-19","label":"Fortrea completed the acquisition"}],"sources":[{"url":"https://www.globenewswire.com/news-release/2026/10/19/3383875/0/en/fortrea-completes-acquisition-of-the-early-phase-services-division-from-worldwide-clinical-trials.html","title":"Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials","publisher":"Fortrea via GlobeNewswire"},{"url":"https://www.worldwide.com/newsroom/worldwide-clinical-trials-completes-divestiture-of-early-phase-services-business-to-fortrea/","title":"Worldwide Clinical Trials Completes Divestiture of Early Phase Services Business to Fortrea","publisher":"Worldwide Clinical Trials"},{"url":"https://www.biobuzz.io/news/north-carolina-life-sciences-news-fortreas-45-million-acquisition-united-therapeutics-fda-approval-more/","title":"North Carolina Life Sciences News: Fortrea's $45 Million Acquisition, United Therapeutics FDA Approval & More","publisher":"BioBuzz"}],"source":{"url":"https://www.globenewswire.com/news-release/2026/10/19/3383875/0/en/fortrea-completes-acquisition-of-the-early-phase-services-division-from-worldwide-clinical-trials.html","publisher":"Fortrea","publishedAt":"2026-10-19T20:05:00.000Z"},"cover":{"url":"https://sotwire.com/covers/fortrea-completes-45-million-worldwide-early-phase-acquisition.webp","alt":"Fortrea closes $45 million deal for Worldwide's early phase unit","provenance":"unknown","provenanceLabel":"Unknown origin","credit":null},"images":[],"provenanceMethod":"EXIF, XMP, and filename heuristic. Not C2PA cryptographic proof, and not a judgment that the depicted event is true.","provenanceDisclaimer":"v1 labels are heuristic (EXIF, XMP, filename), not cryptographic C2PA proof. Treat them as disclosure of observed metadata, not a guarantee that the image is genuine or that the depicted event is true.","citation":"Sotwire Desk, Fortrea. \"Fortrea closes $45 million deal for Worldwide's early phase unit.\" Sotwire, October 26, 2026, https://sotwire.com/stories/fortrea-completes-45-million-worldwide-early-phase-acquisition. Record ID: st_kxkhega45d94dwk0. Desk reported.","sampleLabel":null,"correctionStatus":"No public corrections recorded","integrity":{"algorithm":"sha-256","hex":"2a4bdc80c4c34e6ea8a7e00687c7cc712973b58e730f8910fb13246a0f89d03d","contentDigest":"sha-256=:KkvcgMTDTm6op+AGh8fMcSlztY5zD4kQ+xMkag+J0D0=:","scope":"Canonical JSON record excluding the integrity object"}}